274 related articles for article (PubMed ID: 22793267)
1. The evolving treatment paradigm in myelofibrosis.
Mesa RA
Leuk Lymphoma; 2013 Feb; 54(2):242-51. PubMed ID: 22793267
[TBL] [Abstract][Full Text] [Related]
2. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
Randhawa J; Ostojic A; Vrhovac R; Atallah E; Verstovsek S
J Hematol Oncol; 2012 Aug; 5():43. PubMed ID: 22852872
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Verstovsek S
Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
[TBL] [Abstract][Full Text] [Related]
4. JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Bose P; Verstovsek S
Blood; 2017 Jul; 130(2):115-125. PubMed ID: 28500170
[TBL] [Abstract][Full Text] [Related]
5. The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
Ikeda K; Ueda K; Sano T; Ogawa K; Ikezoe T; Hashimoto Y; Morishita S; Komatsu N; Ohto H; Takeishi Y
Intern Med; 2017; 56(13):1705-1710. PubMed ID: 28674362
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera.
Alchalby H; Kröger N
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S36-41. PubMed ID: 25486953
[TBL] [Abstract][Full Text] [Related]
7. [Not Available].
Soret J; Kiladjian JJ
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S29-38. PubMed ID: 27494970
[TBL] [Abstract][Full Text] [Related]
8. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2023 May; 98(5):801-821. PubMed ID: 36680511
[TBL] [Abstract][Full Text] [Related]
9. Value and pitfalls of assessing bone marrow morphologic findings to predict response in patients with myelofibrosis who undergo hematopoietic stem cell transplantation.
Khanlari M; Wang X; Loghavi S; Wang SA; Li S; Thakral B; Bueso-Ramos CE; Yin CC; Kanagal-Shamanna R; Khoury JD; Patel KP; Popat UR; Medeiros LJ; Konoplev S
Ann Diagn Pathol; 2022 Feb; 56():151860. PubMed ID: 34823075
[TBL] [Abstract][Full Text] [Related]
10. New drugs for the treatment of myelofibrosis.
Mesa RA
Curr Hematol Malig Rep; 2010 Jan; 5(1):15-21. PubMed ID: 20425392
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective.
Savani M; Dulery R; Bazarbachi AH; Mohty R; Brissot E; Malard F; Bazarbachi A; Nagler A; Mohty M
Br J Haematol; 2021 Nov; 195(4):495-506. PubMed ID: 33881169
[TBL] [Abstract][Full Text] [Related]
12. How I treat myelofibrosis.
Cervantes F
Blood; 2014 Oct; 124(17):2635-42. PubMed ID: 25232060
[TBL] [Abstract][Full Text] [Related]
13. Splenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation.
Barabanshikova MV; Zubarovsky IN; Savrasov VM; Korolkov AJ; Baykov VV; Botina AV; Vlasova JJ; Moiseev IS; Darskaya EI; Morozova EV; Afanasyev BV
Hematol Oncol Stem Cell Ther; 2019 Sep; 12(3):140-145. PubMed ID: 30978308
[TBL] [Abstract][Full Text] [Related]
14. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
Gregory SA; Mesa RA; Hoffman R; Shammo JM
Clin Adv Hematol Oncol; 2011 Sep; 9(9 Suppl 22):1-16. PubMed ID: 22362131
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Myelofibrosis: A Moving Target.
Cerquozzi S; Farhadfar N; Tefferi A
Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
[TBL] [Abstract][Full Text] [Related]
16. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.
Stein BL; Gotlib J; Arcasoy M; Nguyen MH; Shah N; Moliterno A; Jamieson C; Pollyea DA; Scott B; Wadleigh M; Levine R; Komrokji R; Klisovic R; Gundabolu K; Kropf P; Wetzler M; Oh ST; Ribeiro R; Paschal R; Mohan S; Podoltsev N; Prchal J; Talpaz M; Snyder D; Verstovsek S; Mesa RA
J Natl Compr Canc Netw; 2015 Apr; 13(4):424-34. PubMed ID: 25870379
[TBL] [Abstract][Full Text] [Related]
17. Advances in the management of myelofibrosis.
Komrokji RS; Verstovsek S; Padron E; List AF
Cancer Control; 2012 Oct; 19(4 Suppl):4-15. PubMed ID: 23042420
[TBL] [Abstract][Full Text] [Related]
18. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
Tefferi A
Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
[TBL] [Abstract][Full Text] [Related]
19. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
20. Ruxolitinib.
Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]